EUR-Lex & EU Commission AI-Powered Semantic Search Engine
Modern Legal
  • Query in any language with multilingual search
  • Access EUR-Lex and EU Commission case law
  • See relevant paragraphs highlighted instantly
Start free trial

Similar Documents

Explore similar documents to your case.

We Found Similar Cases for You

Sign up for free to view them and see the most relevant paragraphs highlighted.

Case T-688/19: Judgment of the General Court of 2 March 2022 — VeriGraft v Eismea (Arbitration clause — Grant agreement concluded in the context of the ‘Horizon 2020’ Framework Programme for Research and Innovation — Termination of the agreement — Misconduct — Capacity as beneficiary of the grant or as a natural person acting in his or her name or on his or her behalf)

ECLI:EU:UNKNOWN:62019TA0688

62019TA0688

March 2, 2022
With Google you find a lot.
With us you find everything. Try it now!

I imagine what I want to write in my case, I write it in the search engine and I get exactly what I wanted. Thank you!

Valentina R., lawyer

10.5.2022

Official Journal of the European Union

C 191/26

(Case T-688/19) (<span class="oj-super oj-note-tag">1</span>)

(Arbitration clause - Grant agreement concluded in the context of the ‘Horizon 2020’ Framework Programme for Research and Innovation - Termination of the agreement - Misconduct - Capacity as beneficiary of the grant or as a natural person acting in his or her name or on his or her behalf)

(2022/C 191/34)

Language of the case: English

Parties

Applicant: VeriGraft AB (Gothenburg, Sweden) (represented by: P. Hansson and A. Johansson, lawyers)

Defendant: European Innovation Council and SMEs Executive Agency (represented by: A. Galea, acting as Agent, and by D. Waelbroeck and A. Duron, lawyers)

Re:

Application based on Article 272 TFEU seeking a declaration of invalidity of the termination by the Executive Agency for Small and Medium-sized Enterprises (EASME) of the grant agreement concerning the project ‘Personalised Tissue Engineered Veins as the first Cure for Patients with Chronic Venous Insufficiency — P-TEV’, concluded in the context of the instrument to support innovation in small and medium-sized enterprises of Horizon 2020 — the Framework Programme for Research and Innovation (2014-2020).

Operative part of the judgment

The Court:

1.Declares that the termination by the Executive Agency for Small and Medium-sized Enterprises of the grant agreement for the project ‘Personalised Tissue Engineered Veins as the first Cure for Patients with Chronic Venous Insufficiency — P-TEV’, bearing reference 778620, is invalid;

2.Orders the European Innovation Council and SMEs Executive Agency to pay the costs.

(<span class="oj-super">1</span>) OJ C 432, 23.12.2019.

EurLex Case Law

AI-Powered Case Law Search

Query in any language with multilingual search
Access EUR-Lex and EU Commission case law
See relevant paragraphs highlighted instantly

Get Instant Answers to Your Legal Questions

Cancel your subscription anytime, no questions asked.Start 14-Day Free Trial

At Modern Legal, we’re building the world’s best search engine for legal professionals. Access EU and global case law with AI-powered precision, saving you time and delivering relevant insights instantly.

Contact Us

Tivolska cesta 48, 1000 Ljubljana, Slovenia